trending Market Intelligence /marketintelligence/en/news-insights/trending/zutq34fnmbatsmwva9cicq2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Report: Johnson & Johnson might break up Actelion in acquisition

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry

Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets


Report: Johnson & Johnson might break up Actelion in acquisition

Johnson & Johnson is in talks to break up Actelion Ltd. in its proposed acquisition, Reuters reported Dec. 29, citing "people familiar with the matter."

The deal would reportedly involve the separation of the Swiss biotechnology company's commercialized portfolio from its research and development assets, which would be placed in a new publicly traded company.

Reuters reported that Johnson & Johnson could offer Actelion around $260 per share in the deal, compared to its previously rejected offer that valued Actelion at about $26 billion.

The ownership and management structure for the new company is still being hashed out in the discussions, according to the anonymous sources.

A deal could reportedly be finalized by late January 2017.

The companies recently re-entered negotiations after the previous talks for a deal fell apart. French drugmaker Sanofi is also in advanced talks to acquire Actelion.